Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Inflammatory and metabolic gene signatures predict overall survival and response to venetoclax-based therapy in TP53 mutant AML

View Full Paper
Ask AI
Bookmark
Share

Authors

JVJayakumar VadakekolathuEFElena M. FenuKBKate Bennett

Discussion

Loading...

Member takes

Overview

Spatial transcriptomic analysis shows immune and metabolic signatures impacting survival in TP53 mutant AML, suggesting resistance to venetoclax-based therapy.

Key Points

  • Short overall survival is significantly linked to immune checkpoints and IL2/IL6 signaling pathways.
  • Gene expression analysis revealed pathways involving reactive oxygen species among TP53 mutant AML.
  • Spatial transcriptomics identified critical tumor microenvironment factors affecting treatment responses.
  • Findings suggest the necessity of tailored therapeutic approaches for TP53 mutant acute myeloid leukemia.

Cite This Study

Vadakekolathu et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0achttps://doi.org/10.1182/blood-2025-1734
View Full Paper
Ask AI
Bookmark
Share